In discussing how to best manage these issues in the COVID-19 pandemic at present, we identify gaps in the literature and policy important to clinicians as this crisis continues.
This study showed that the ECMO group exhibited a significantly lower mortality rate compared with the MV alone group at 90, 30 and 60 days for severe ARDS patients.
The HEMOCHRON® instruments(Models 401 and 801)are portable, battery operated instruments designed toperform an array of whole blood coagulation tests at any patient location.
